

COPD exacerbations · 2: Aetiology

E Sapey, R A Stockley

Thorax 2006;61:250–258. doi: 10.1136/thx.2005.041822

Exacerbations of COPD are thought to be caused by complex interactions between the host, bacteria, viruses, and environmental pollution. These factors increase the inflammatory burden in the lower airways, overwhelming the protective anti-inflammatory defences leading to tissue damage. Frequent exacerbations are associated with increased morbidity and mortality, a faster decline in lung function, and poorer health status, so prevention or optimal treatment of exacerbations is a global priority. In order to evolve new treatment strategies there has been great interest in the aetiology and pathophysiology of exacerbations, but progress has been hindered by the heterogeneous nature of these episodes, vague definitions of an exacerbation, and poor stratification of known confounding factors when interpreting results. We review how an exacerbation should be defined, its inflammatory basis, and the importance of exacerbations on disease progression. Important aetiologies, with their potential underlying mechanisms, are discussed and the significance of each aetiology is considered.

symptoms vary between individuals,⁴ the most common being breathlessness, wheeze, chest tightness, increased cough, and increased sputum volume and purulence.⁵ Non-specific symptoms are also common (including fatigue and general malaise),⁵ as are small but significant changes in objective measurements such as a transient reduction in forced expiratory volume in 1 second (FEV₁), forced vital capacity (FVC), and peak expiratory flow (PEF).³ However, no single or group of symptoms or measurements are diagnostic for an exacerbation, so working definitions have arisen from research to assess the clinical condition of the patients and to evaluate their responses to treatment.

The most referenced definition remains Anthonisen *et al*⁶ which divided patients into three groups according to their symptomatology. Type 1 exacerbations were defined by the presence of increased breathlessness, sputum volume and sputum purulence; type 2 by the presence of two of these symptoms, and type 3 by the presence of one of these symptoms in addition to one of the following: an upper respiratory tract infection in the past 5 days, fever without other cause, increased wheezing or cough, or an increase in heart rate or respiratory rate by 20% compared with baseline readings. This definition was devised prospectively to analyse the effect of antibiotics on exacerbations and not to structure patient management. More recent studies have adapted these criteria with varying degrees of success.

In order to compare studies and to clarify management strategies, a consensus definition is required. The Aspen workshop⁷ defined AECOPD as “a sustained worsening of the patient’s condition from the stable state and beyond normal day to day variations, that is acute in onset and necessitates a change in regular medication in a patient with underlying COPD”. While a sound description of an exacerbation, when used alone, the definition is still unwieldy as it provides no clear definition of “sustained” (the authors explain that this should be for longer than 24 hours but that acute presentations should not be excluded) nor clear guidance on how “worsening of the patients condition” should be assessed. However, when used with validated daily diary cards, the definition becomes more structured with a

Chronic obstructive pulmonary disease (COPD) is a progressive chronic disease which is characterised by an inexorable decline in respiratory function, exercise capacity, and health status.¹ This underlying state is interrupted by exacerbations of symptoms which vary in severity and frequency both between patients and during the course of one patient’s illness. These exacerbations are important, not only because of their impact on an individual’s life but also because of their long term effects on health status, morbidity, and mortality. In fact, exacerbation frequency is one of the most important determinants of health related quality of life.² Exacerbations are a significant cause of hospital admission and readmission, and the burden placed on health resources is immense.³ Just as COPD as an entity is heterogeneous, so are exacerbations, and despite wide scientific interest in these episodes, there is still much debate regarding how exacerbations should be defined, their aetiology, and their prognostic significance.

DEFINITION

Given the heterogeneity and the complexity of COPD in the stable state, it is perhaps understandable that there is no standardised definition of an acute exacerbation of COPD (AECOPD) in research or in clinical practice. Exacerbation

Abbreviations: AECOPD, acute exacerbation of chronic obstructive pulmonary disease; CRP, C-reactive protein; CXCL8, interleukin 8; E selectin, endothelial selectin; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; GRO α , growth-related oncogene α ; IL, interleukin; LTB₄, leukotriene B₄; NE, neutrophil elastase; PEF, peak expiratory flow; sICAM-1, soluble intracellular adhesion molecule 1; SLPI, secretory leukoproteinase inhibitor; TNF α , tumour necrosis factor α

See end of article for authors’ affiliations

Correspondence to: Professor R A Stockley, Lung Investigation Unit, Nuffield House, Queen Elizabeth Hospital, Birmingham B15 2TH, UK; r.a.stockley@bham.ac.uk

Received 4 July 2005
Accepted
7 November 2005

means for differentiating between day to day symptom variability and true exacerbations.

It may be that a concise and readily applicable definition cannot be reached until we have a sound understanding of the inflammatory process which underpins the clinical presentation. Once this is achieved, a biomarker may present itself as indicative of an exacerbation when raised to a significant degree and, indeed, may characterise the aetiology.

INFLAMMATORY CHANGE AND AECOPD

There is a substantial and cogent body of evidence that airway inflammation is prevalent in stable COPD and is fundamental to its pathogenesis. Neutrophil proteinases, especially neutrophil elastase (NE), have been shown to cause all components of COPD, including emphysema, mucous gland hyperplasia and mucus hyper secretion,⁸ and studies have shown that smokers have increased numbers of neutrophils in lung tissue,⁹ sputum,^{10 11} and bronchoalveolar lavage (BAL) fluid.¹² Many inflammatory proteins have been found to be raised in stable COPD compared with healthy controls who smoke, including tumour necrosis factor α (TNF α), interleukin-1 β (IL-1 β), and the chemoattractants leukotriene B4 (LTB4), interleukin 8 (CXCL8), and growth-related oncogene α (GRO α).^{13–15}

There is evidence that inflammation is amplified during exacerbations, but studies have been small and have varied in their definitions of an exacerbation. Increased neutrophil counts have been found in the bronchial walls and in BAL fluid samples from patients during exacerbations of COPD,^{16 17} with increased neutrophil sequestration in the pulmonary microcirculation prior to migration into the airways.¹⁸ Increases in various inflammatory markers have also been found at COPD exacerbation compared with the stable state, including inflammatory cytokines, IL-6, CXCL8, endothelin-1, the neutrophil chemoattractant (LTB4), and NE (table 1).^{19–21}

In one recent study CXCL8, soluble intracellular adhesion molecule 1 (sICAM-1), and soluble endothelial selectin (E selectin) (all of which are required for neutrophil migration from the circulation into airspaces) were higher in patients with COPD who were hospitalised for an acute exacerbation than in healthy controls and those with stable COPD. Furthermore, serum levels of CXCL8 and sICAM declined significantly during treatment.²² The rise in inflammatory cells and proteins during an exacerbation and the subsequent reduction with symptom resolution suggests a causative link between excess inflammation and symptomatology, but this finding has not been reproduced in all studies (table 1). In another recent study, serum levels of TNF α , IL-6, CXCL8 and C-reactive protein (CRP) were measured in patients with severe COPD admitted with respiratory failure due to an exacerbation. Although levels of CRP and IL-6 were raised, there was no significant change during recovery.²³ The disparity in results may be explained by the small numbers in each study and the wide heterogeneity of exacerbations since clear rises and falls in CRP have been noted by others at the start and resolution of the episode.²⁴ However, it is of fundamental importance to understand the impact of each exacerbation on the disease process. There are conflicting data as to whether exacerbations are associated with a step-like decline in physiology or whether patients generally return to their pre-exacerbation status. If inflammatory markers do not return to pre-exacerbation levels, it is likely that the increased ongoing inflammation would influence the subsequent decline in lung function.

The high levels of inflammatory proteins and neutrophils within the lung are believed to initiate the pathology seen in COPD. Environmental pollution, cigarette smoke, and

adherent pathogens activate respiratory epithelial cells and phagocytes. These cells initiate a complex inflammatory cascade, with secretion of pro-inflammatory proteins by epithelial and endothelial cells, leucocytes, and other cells in the connective tissue.¹ Some of these proteins (including LTB4 and CXCL8) can stimulate neutrophil migration towards the site of injury by means of a chemoattractant gradient.³² To pass through connective tissue, neutrophils are believed to release enzymes which degrade components of the extracellular matrix; once released, these proteinases diffuse away from the neutrophil. Initially, the concentration of proteinases far exceeds the concentration of resident anti-proteinases (such as α_1 -antitrypsin), so proteolysis occurs unabated; however, once the concentration of proteinases equals the levels of anti-proteinases, they are irreversibly inactivated so tissue damage is limited.³³ Close to the neutrophil, therefore, there is an area of obligate proteolysis which allows passage through the matrix while tissue is protected further away.

In patients with α_1 -antitrypsin deficiency, lung levels of the inhibitor are low. There is an imbalance between proteinases and anti-proteinases and normal inactivation of proteinases is reduced and the area of obligate proteolysis is increased, leading to widespread tissue damage that is thought to be crucial to disease progression.^{34 35} In COPD there is a similar imbalance between proteinases and anti-proteinases—at least during exacerbations—with more pro-inflammatory proteins, the recruitment and activation of inflammatory cells, and the potential for more tissue damage during cell emigration, degranulation, and secretion in situ. This is reflected in the detection of active enzymes in the secretions during such episodes.²⁵

Although the role of other cells and proteinases has been implicated in the distal lung, the neutrophil remains the cell central to many of the features and effects of exacerbations in the more proximal airways. The neutrophil is a green cell due to the presence of myeloperoxidase (MPO) in its azurophilic granules,³⁶ and the sputum appears green (purulent) when it contains high numbers of neutrophils.³⁷ It has been shown that neutrophil recruitment is increased during lower respiratory tract bacterial infections,²⁵ which can be identified by the presence of purulent sputum using a simple graded colour chart.³⁸ This provides one distinct identifying feature of some episodes that is clearly associated with the presence of excess elastase activity.²⁴

IMPORTANCE OF EXACERBATIONS

Acute exacerbations are an important cause of mortality and morbidity in patients with COPD.³⁹ In 1996 a study of survival following hospital admission for acute exacerbations reported in-hospital mortality rates of 11% and 1 year mortality rates of 43%.⁴⁰ A more recent study reported in-hospital mortality at 8% with a 1 year mortality rate of 23%,⁴¹ confirming the prognostic importance of these episodes.

Exacerbations have a marked effect on the quality of life of patients. Frequent exacerbations (more than two per year) have been associated with more dyspnoea and reduced exercise capacity,⁴² a greater decline in health status,^{2 43} and a greater likelihood of becoming housebound⁴⁴ than in patients with fewer acute episodes.

It is understandable that repeated exacerbations should be associated with a faster decline in lung function. The urinary excretion of desmosine and isodesmosine (byproducts of lung elastin degradation) are raised in exacerbations compared with the stable state,⁴⁵ and higher levels of these proteins have been associated with a faster decline in FEV₁ in COPD.⁴⁶ In a 15 year study, increased sputum neutrophil counts (as found during bacterial exacerbations) have been correlated with a rapid decline in FEV₁¹¹ and, in another study, the

Table 1 Inflammatory cells and proteins raised in exacerbations of COPD

	Raised marker	Medium	Evidence of resolution	Reference
(1)	MPO CXCL8 NE LTB4 Sol:serum albumin ratio CRP	Sputum (in purulent samples only) Sputum and serum Serum	LTB4 only	25
(2)	TNF α CXCL8	Sputum	Both declined to pre-exacerbation levels	26
(3)	MPO NE LTB4 Sol:serum albumin ratio	Sputum with bacterial eradication Sputum and serum	Reduction in MPO and LTB4	27
(4)	RANTES CXCL8 Neutrophil Eosinophils ECP NE	Sputum	Not studied	28
(5)	CXCL8 ICAM-1 E-selectin H ₂ O ₂	Plasma EBC	Plasma CXCL8 and sICAM1 reduced significantly. E-selectin did not. H ₂ O ₂ significantly reduced	29
(6)	CRP CXCL8 IL-6	Plasma	No resolution	23
(7)	H ₂ O ₂ CRP ESR MPO	EBC Serum	Resolution following recovery	30
(8)	Eosinophil RANTES	Bronchial biopsies	Not studied	31
(9)	Neutrophil Eosinophil GM-CSF	BAL	Not studied	16

MPO, myeloperoxidase; NE, neutrophil elastase; LTB4, leukotriene B4; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; CXCL8, interleukin 8; H₂O₂, hydrogen peroxide; GM-CSF, granulocyte-macrophage colony stimulating factor; EBC, exhaled breath condensate; BAL, bronchoalveolar lavage fluid.

extent of emphysema (quantified by computed tomography) correlated with the number of previous exacerbations.⁴⁷

It may be that patients who experience frequent AECOPD have increased bronchial inflammation in the stable state compared with those with fewer episodes. Bhowmik *et al*¹⁹ found a relationship between stable state CXCL8 and IL-6 concentrations in induced sputum and exacerbation frequency. However, this study did not account for important confounding factors such as the presence or absence of bronchiectasis, chronic bronchitis, treatment with inhaled steroids, degree of pulmonary impairment, smoking status, or bacterial colonisation (all of which influence inflammation⁴⁸). Gompertz *et al*¹⁹ accounted for the above factors and found no difference in pro-inflammatory mediators between frequent and less frequent exacerbators. The only difference noted was the concentration of the anti-proteinase secretory leukoproteinase inhibitor (SLPI) which was reduced in the sputum of patients with frequent exacerbations. The authors speculated that reduced activity of SLPI (which has been shown to have antibacterial and antiviral functions *in vitro*⁵⁰) may predispose towards infective exacerbations, which has been supported by studies of recurrent mucosal infections outside the lung.⁵¹

The underlying aetiology of the exacerbation may also affect FEV₁ decline, as Wilkinson *et al* described the greatest reduction in FEV₁ (56 ml in 1 year) in patients with a higher

airway bacterial load, and this decline was greater still in patients with a change in bacteria as opposed to a single colonising species.⁵²

CAUSES OF ACUTE EXACERBATIONS OF COPD

Published data suggest that 50–70% of exacerbations are due to respiratory infections⁵³ (including bacteria, atypical organisms and respiratory viruses), 10% are due to environmental pollution (depending on season and geographical placement),⁵⁴ and up to 30% are of unknown aetiology.⁴⁰

Role of bacterial infections

Studies using bronchoscopic sampling of the lower airways have found a relationship between bacteria and exacerbations with approximately 30% of sputum cultures and 50% of bronchial secretion cultures associated with the presence of a potential pathogenic bacteria.^{55–56} In severe exacerbations requiring ventilatory support, this number is even higher (over 70%).^{57–58} Commonly isolated organisms include *Haemophilus influenzae* (11% of all exacerbating patients), *Streptococcus pneumoniae* (10%), *Moraxella catarrhalis* (10%), *Haemophilus parainfluenzae* (10%), and *Pseudomonas aeruginosa* (4%), with Gram negative bacteria occurring more rarely (data taken from four studies^{55–58}). It appears that infections with *Pseudomonas* spp, *Stenotrophomonas* spp, and Gram negative bacteria occur in more severe exacerbations, affect-

Table 2 Causes of COPD exacerbations

Bacteria
<i>H influenzae</i>
<i>S pneumoniae</i>
<i>M catarrhalis</i>
<i>Staphylococcus aureus</i>
<i>P aeruginosa</i>
Viruses
Rhinovirus (common cold)
Influenza
Parainfluenza
Coronavirus
Adenovirus
Respiratory syncytial virus
Picornavirus
Metapneumovirus
Atypical organisms
<i>M pneumoniae</i>
<i>C pneumoniae</i>
Pollutants
Nitrogen dioxide
Particulates (PM ₁₀)
Sulphur dioxide
Ozone

ing the most debilitated patients.^{58–59} This may reflect previous antibiotic pressure, but more research is required to link patient characteristics with likely pathogens (table 2).

Following bacterial exacerbations, patients develop new strain-specific antibodies as part of their immune response. Sethi *et al*⁶⁰ studied this phenomenon and described antibodies to surface exposed epitopes on *H influenzae* after exacerbations. These antibodies were extremely strain-specific, showing bactericidal activity for only 11 of 90 heterologous strains. Furthermore, a recent study found *Moraxella catarrhalis* in approximately 10% of exacerbations with organism clearance occurring after 30 days, and again there was evidence of strain-specific immunity.⁶¹ The development of a new immune response supports the hypothesis that bacteria cause exacerbations, and the specificity of this response provides an explanation for recurrent exacerbations (with infection by the same bacterial species but a different genetic strain).

There are a number of mechanisms by which bacteria could affect symptoms in COPD. *S pneumoniae*, *H influenzae* and *P aeruginosa* have been shown to induce mucus hypersecretion *in vitro*.⁶² The latter two organisms have also been shown to reduce ciliary beat frequency,⁶³ and *H influenzae* can cause epithelial damage during adherence.⁶⁴ Bacteria enhance pulmonary inflammation in COPD, which could potentially cause increased tissue damage due to leucocyte recruitment and proteinase secretion. The isolation of potentially pathogenic bacteria in BAL fluid from COPD patients during bronchoscopy is associated with a higher neutrophil count and higher TNF α levels in BAL fluid than in culture negative patients.⁶⁵ The bacterial load is proportional to pro-inflammatory mediators irrespective of the pathogen present,³⁷ although some bacteria are associated with a greater response than others. *In vitro* studies have demonstrated higher levels of IL-6, CXCL8, and TNF α release following infection with *H influenzae*,⁶⁶ and studies in man have shown higher concentrations of TNF α in the sputum of patients with positive cultures for this organism.⁶⁷ White *et al*²⁷ showed that eradication of bacteria was associated with a corresponding resolution of inflammation (including MPO, used as a surrogate marker for neutrophils, and LTB₄), while a continued bacterial presence was associated with a lesser reduction. This provides further support for the hypothesis that bacteria cause exacerbations and that the size of the load determines the degree of inflammation.

If bacteria are the cause of at least 50% of exacerbations, one might expect a significant clinical response to antibiotics; however, many controlled trials of antibiotic therapy show little or no benefit with treatment.^{68–69} This may be explained by small patient numbers, poor identification of patients who were likely to have bacterial exacerbations of COPD before starting treatment, choice of antibiotic, and the end points measured. As stated previously, high neutrophil counts and increasing concentrations of MPO in sputum cause increasing sputum purulence.⁶⁹ MPO concentrations are proportional to bacterial load, with increasing likelihood of bacterial isolation in culture as sputum darkens. When only purulent exacerbations are treated with antibiotics, a clear clinical and biological improvement is seen.²⁴

Although some studies have shown that the likelihood of isolating potentially pathogenic bacteria is increased during exacerbations (with increased bacterial numbers compared with the stable state),^{24 55–57 70} others (using sputum cultures) have not,^{71 72} and these negative findings have questioned the role of bacteria during acute episodes. However, these older studies must be interpreted with caution.

Firstly, there is some evidence to suggest that standard sputum cultures may miss the presence of bacteria in the lung both during the stable state and during exacerbations. An American study demonstrated the presence of intracellular *H influenzae* in 87% of bronchial biopsy samples from patients with COPD during an acute exacerbation, compared with 33% of patients with stable COPD and none in healthy controls. However, standard microbiological sampling techniques identified bacteria in only 7% of the same acutely unwell patients.⁷³ A more recent study found positive sputum cultures in only 21% of patients with COPD persistently colonised with the same strain of *H influenzae*, with strain-specific *H influenzae* genes seen in both positive and negative sputum cultures.⁷⁴ Negative sputum cultures may be explained by the presence of low concentrations of bacteria during colonisation (less than 10³ colony forming units/ml sputum will yield negative cultures) or the sensitivity of culture techniques to certain bacteria.

Secondly, many older studies were unable to differentiate between strains of bacteria as molecular techniques were unavailable at the time. Authors described the presence of the same bacteria during stable periods and exacerbations, thereby discounting their role,^{71 72} but would have been unable to appreciate differences in genotype which indicate the presence of a different strain of the same species⁷⁵ or the overall bacterial load.

Bacterial colonisation

Approximately 20–30% of patients with COPD have positive sputum bacterial cultures when clinically stable,^{72 76 77} and the presence of bacteria has been shown to be related to the degree of airflow obstruction and current cigarette smoking status.⁷⁸ However, there remains controversy as to whether bacterial colonisation causes a deterioration in COPD or whether colonisation is simply a marker of disease severity when mucociliary clearance is likely to be impaired as a result of epithelial damage. It is also unclear whether asymptomatic colonisation leads to exacerbations caused by the same bacterial strain, or whether colonisation predisposes towards new bacterial growth. The presence of bacteria already suggests a breach of host defences with associated epithelial cell damage, mucus hypersecretion, reduced ciliary beat frequency, increased submucosal vascular leakage, and inflammatory cell infiltration. It therefore seems likely that patients with chronic colonisation would have a greater inflammatory burden, more frequent exacerbations, and a faster decline in lung function. Indeed, this has been shown in other inflammatory respiratory conditions such as cystic

fibrosis and bronchiectasis,^{79, 80} and a number of studies have aimed to clarify this point in COPD.

Bogaert *et al* studied 269 patients with mild to severe COPD, collecting four sputum samples over a 10 month period in cases of stable disease and collecting at least one sample during an exacerbation. 34% of patients had positive sputum cultures for one potential pathogen while stable and 49% had positive sputum cultures during exacerbations. The most common colonising organisms were *H influenzae* (19%), *S pneumoniae* (13%), and *M catarrhalis* (9%). Interestingly, only colonisation with a monoculture of *S pneumoniae* predisposed towards frequent exacerbations once potential confounding factors were taken into account.⁵⁹

Patel *et al*⁷⁰ found higher rates of colonisation in a smaller study of 29 patients with moderate to severe COPD; 51% of patients were colonised by one or more possible pathogens, with *H influenzae* present in 53% of patients with positive cultures, *S pneumoniae* in 33%, and *H parainfluenzae*, *M catarrhalis*, and *P aeruginosa* in 20%.

Hill *et al*⁷⁷ showed that colonisation was associated with increased inflammation (with increased neutrophil counts, and increased CXCL8, LTB4 and MPO) and that bacterial load was proportional to the inflammatory response seen. Bacterial loads of $<10^6$ colony forming units (cfu) were not associated with neutrophilic inflammation (and represented low level, stable colonisation), while loads of $>10^6$ cfu were associated with increased neutrophil influx to pro-migratory inflammatory proteins.

Colonisation does not appear to be static as changes in bacterial strain, species, and load have been seen with sequential sampling in individual patients. In a study of 30 stable COPD patients with positive sputum cultures, a change in colonising bacterial type was associated with a greater decline in FEV₁ and higher levels of inflammatory proteins than persistent colonisation with the same bacteria; the higher the bacterial load, the more pronounced the decline in lung function and the increase in inflammation.⁵² The authors suggest that higher bacterial loads would stimulate the release of more pro-migratory cytokines leading to more neutrophils and therefore more proteinase induced lung damage. In the presence of a new type of bacteria, there may be an enhanced inflammatory reaction leading to a faster decline in lung function via the same pathway.

In support of this, Patel and colleagues⁷⁰ found a positive correlation between lower airway colonisation, exacerbation frequency and CXCL8 concentration in the sputum. Colonisation may also affect the severity of an exacerbation as the presence of *H influenzae* when stable was associated with more symptom reporting and increased sputum purulence during the exacerbations. Also, although results did not reach significance, there was a notable trend between colonisation and the duration of an exacerbation.

In a recent study of COPD, a comparison was made between colonising and exacerbation strains of *H influenzae*. Colonising strains were defined by the presence of a bacterial strain with no clinical signs of exacerbation and no new serum antibody response to the bacterial strain. Exacerbating strains were defined by the presence of a bacterial strain at symptom onset and new bactericidal antibodies to the bacterial strain 1 month later.⁸¹ Using a mouse model and cell cultures, the exacerbating strains of *H influenzae* caused more neutrophil recruitment, adhered to epithelial cells in higher numbers, and (in cell cultures) induced more CXCL8 release from epithelial cells than colonising strains. Similar findings have been reported by Sethi *et al*⁸² who found that more exacerbations were associated with a new strain or type of bacteria than with a previously colonising strain. However, a study by Bresser *et al*⁸⁷ described contradictory results, with 67% of exacerbations being due to a previously colonising

bacteria strain and 86% of new strain acquisitions occurring without an exacerbation. The difference in results is not unexpected because the interactions between host and pathogen are complex, strains of bacterial pathogens differ in virulence with a degree of subtlety that may not be easily detected, and there is great interpatient variability in the intensity and duration of the inflammatory response.

Despite continued debate, there is compelling evidence that bacteria do cause exacerbations of COPD, with greater bacterial loads seen in bronchoscopic "protected specimen brush" sampling compared with the stable state,⁵⁵ more airway inflammation²⁵ with resolution of inflammation if bacteria are eradicated,²⁷ and a new immune response seen following infection.^{60, 61} However, it is still unclear whether exacerbations are due to colonising strains that undergo mutation or to new bacterial strains or bacterial species. Nevertheless, there is evidence that colonised patients experience more exacerbations and have more inflammation and perhaps a faster deterioration in lung function.

Role of viral infections

Viral infections of the respiratory tract are a common cause of morbidity and it is unclear whether patients with COPD are more susceptible to these infections than healthy individuals. Some studies have isolated viruses more frequently in COPD patients^{83, 84} while others have not.^{85, 86} Certainly, exacerbations have been associated with a prodrome of coryzal symptoms and are more frequent in winter months when viral infections are more common in the community.⁸⁷ Many studies have provided only indirect evidence of a viral aetiology of AECOPD as they have relied on the presence of serological conversion as a marker of infection,^{83, 88} although some recent studies have used more robust techniques including viral culture⁸⁵ and polymerase chain reaction (PCR) to identify viral RNA or DNA sequences.⁸⁹ However, there is evidence that at least a proportion of episodes are associated with viral isolation. Cell culture and serological studies suggest that viral infections are the likely cause of approximately 20% of exacerbations,⁹⁰⁻⁹² while PCR studies have suggested that up to 40% of acute respiratory infections in COPD are associated with viruses.⁹³

Serological evidence of infection with influenza virus has been detected in 5–28% of patients following an exacerbation, but is present in only 6% of patients who have not had an exacerbation. The prevalent strain of influenza has some effect on exacerbation frequency and severity. A recent American study carried out over four consecutive winters noted that, when the dominant strain of influenza was H1N1 (one not associated with substantial morbidity and mortality in the elderly), hospital admission for influenza related chest infections were low.^{94, 95} In contrast, when H3N2 influenza was prevalent (a more virulent strain), admissions for chest infections and related deaths were significantly raised,^{94, 96} suggesting a cause and effect.

Rhinovirus has been detected in up to 23% of patients during exacerbations but in $<1\%$ of stable patients.⁸⁹ Serological studies have indicated that respiratory syncytial virus (RSV) infection has been associated with up to 6% of exacerbations of COPD, although Falsey *et al*⁹⁷ reported that 11.4% of hospital admissions for COPD could be accounted for by the presence of RSV when diagnosed using serology, reverse transcriptase-PCR, and viral culture. As with other viruses, colonisation with RSV in the stable clinical state has been demonstrated in some studies,^{90, 98} although the significance of these findings is unknown.

Parainfluenza viruses and adenoviruses have been associated with a lower percentage of exacerbations. Recent studies have suggested that picornaviruses, coronaviruses,⁹³ and the newly identified human metapneumovirus⁹⁹ may




Figure 1 Key inflammatory effects of viral infection. Viruses cause increased neutrophil recruitment into airways by several mechanisms. Viral attachment and subsequent epithelial cell damage causes release of reactive oxygen species (ROS) as shown in point A. ROS and activation of inflammatory receptors (such as tumour necrosis factor α (TNF α) binding to its receptor) as shown in point B causes dephosphorylation of nuclear factor kappa B (NF- κ B) (shown in point C) which in turn causes the transcription of inflammatory proteins (D), increasing white cell recruitment to lung tissue (E). Viral attachment and ROS also activate protein kinase C (F) which stimulates further transcription of inflammatory proteins including the precursor of endothelin 1 which is a potent bronchoconstrictor (G). Some viruses (including rhinoviruses) bind to ICAM-1, increasing its expression, which provides a target for neutrophil attachment and migration (H).

also be important causes of acute episodes. However, the role of these pathogens in COPD remains unclear as a positive PCR result without evidence of an acute immune response to the virus is at variance with conventional understanding of an infection. Nevertheless, viruses can affect many aspects of the respiratory tract that can cause damage and inflammation associated with exacerbations (fig 1).

In summary, the association between exacerbations of COPD and the identification of viruses and an appropriate immune response has not been consistent. Overall, the data suggest that viruses do play a role in some episodes, and the variation in frequency of viral identification may be influenced by epidemics present at the time of data collection⁴⁸ as well as the sensitivity of the methods.

Lower respiratory tract viral infections damage the airway epithelium causing loss of ciliated cells, increased plasma exudation, and increased mucus production.¹⁰⁰ Rhinovirus attaches to the airway epithelium through the intercellular adhesion molecule (ICAM)-1, inducing further ICAM-1 expression and thereby promoting neutrophilic recruitment and inflammation.¹⁰¹ Respiratory viruses may also increase the expression of RANTES leading to increased eosinophil recruitment into the airways with associated release of platelet activating factor, major basic protein, cysteinyl leukotrienes, and eosinophil peroxidase.²⁸ Indeed, the association of eosinophilia with some exacerbations is well documented,^{102–103} although it has mainly been seen in patients with milder disease.¹⁰⁴ In vitro, rhinovirus infection induces expression of CXCL10, a ligand for activated T lymphocytes and natural killer cells, and in vivo levels of CXCL10 correlate with symptom severity and viral titres in airway secretions.¹⁰⁵ Rhinovirus infection also increases production of reactive oxidant species and activates nuclear factor- κ B, which is important in the regulation of CXCL8 production.¹⁰⁶

Viral and chlamydial infections have been associated with increased endothelin-1 concentrations in spontaneous and induced sputum.²⁰ Endothelin-1 is a potent bronchoconstrictor produced by bronchial epithelial cells which increases production of IL-6. IL-6 is a pro-inflammatory cytokine which activates lymphocytes and also enhances endothelin-1 production, suggesting a positive feedback loop between these two proteins.¹⁰⁷ Respiratory viruses can also increase the release of acetylcholine by activating M2 muscarinic receptors, also (potentially) leading to bronchoconstriction.¹⁰⁸

Finally, the effects of viral infection may predispose to secondary bacterial infections of the respiratory tract. There appears to be an association between viral and simultaneous or sequential bacterial infection of the airways. Increased isolation of *H influenzae* and *S pneumoniae* has been obtained from sputum in patients with positive viral seroconversion, suggesting that viral infection preceded bacterial infection.¹⁰⁹

Atypical organisms

Mycoplasma pneumoniae and *Chlamydia* spp are intracellular bacteria that share some characteristics of viruses. They are usually diagnosed retrospectively by serological testing and have been implicated in AECOPD. One recent study suggested that up to 14% of exacerbations were associated with mycoplasma.¹¹⁰ Recent animal studies and in vitro work have highlighted a potential mechanism for mycoplasma to induce features of exacerbations as mycoplasma derived lipoproteins activate Toll Like Receptor 2, increasing mucin production.¹¹¹

Meloni *et al*¹¹² described serological and molecular evidence of current *Chlamydia pneumoniae* infection in 8.9% of patients during exacerbations of COPD, while Beaty *et al*¹¹³ found evidence of acute infection in 5% of exacerbations. In vitro work suggests that this organism can also promote features of AECOPD by increasing the secretion of IL-1 β and

decreasing the secretion of its anti-inflammatory counterpart, IL-1 receptor antagonist, thereby potentially increasing inflammatory cell sequestration into the airways.¹¹⁴

NON-INFECTIOUS AETIOLOGIES OF AECOPD

Despite the importance of infections, other factors may provoke exacerbations. In a study of 1016 patients with severe COPD, infection was the proven cause in only 51% of exacerbations. Heart failure was thought to account for 26% of episodes of increased symptoms, but about 30% of exacerbations had no identified aetiology.⁴⁰

Environmental pollution

Epidemiological research has identified more exacerbations during periods of increased pollution.^{115–116} Increases in black smoke particulate matter, sulphur dioxide (SO₂), ozone (O₃), and nitrogen dioxide (NO₂) are associated with increases in respiratory symptoms, admissions for exacerbations, and COPD associated mortality.¹¹⁷ These adverse effects have been most clearly described with high levels of ozone resulting in an increased relative risk of hospital admission with AECOPD^{118–120} and with particulate air pollution comprising 50% organic and 50% inorganic matter of $\leq 10 \mu\text{m}$ diameter (PM₁₀).^{121–122} These studies have concluded that up to 9% of admissions with AECOPD may be due to atmospheric pollution, especially during the summer months.⁵⁴

Pollutants have been shown to be pro-inflammatory. In animal models, SO₂ and PM₁₀ have been shown to increase mucus secretion in airways leading to increased airway resistance and bronchial plugging.¹²³ Intratracheal instillation of PM₁₀ into the lungs of rats causes an influx of neutrophils, a subsequent rise in pro-inflammatory mediators, and increased epithelial permeability,¹²⁴ supporting this concept.

Exposure to diesel exhaust fumes for 1 hour has been shown to induce a marked neutrophil influx into the proximal airways of healthy volunteers with a corresponding increase in CXCL8, GRO α , and IL-5 levels in bronchial washings.¹²⁵ There was also an increase in the expression of transcription factors (such as NF κ B, c-jun and c-fos) in bronchial biopsies,¹²⁶ consistent with oxidative stress triggering the increased synthesis of pro-inflammatory cytokines. Exposure to ozone is associated with increased nasal inflammation in non-atopic children,¹²⁷ and SO₂ and NO₂ enhance the response to inhaled allergens.¹²⁸

Mucus hypersecretion and ciliary damage are features of COPD¹ and would be expected to impair clearance of inhaled particles or soluble gases. This may make the patient more susceptible to the pro-inflammatory effects of inhaled pollutants¹²⁰ which, in turn, would lead to more mucus secretion, airway oedema, and neutrophil recruitment and activation, all of which are features of AECOPD.

Miscellaneous

Exacerbations and a decline in FEV₁ have also been associated with a fall in outdoor or indoor room temperature, suggesting a cause and effect. However, coryzal symptoms are also more common during colder periods, and the increase in exacerbation frequency could be accounted for by viruses rather than the physical effects of temperature.¹²⁹

Despite some patient concerns, there is no evidence that influenza vaccination is associated with AECOPD. Indeed, two recent studies reported no ill effects (with no changes in dyspnoea, exercise capacity, lung function or exacerbation frequency) following vaccination, irrespective of the severity of the disease.^{130–131}

CONCLUSIONS

There have been significant advances in our understanding of the aetiology and pathogenesis of acute exacerbations of

COPD. Exacerbations appear to be related to heightened airway inflammation which leads to the composite of symptoms seen during these acute episodes. The evidence suggests that bacteria, viruses, and environmental pollution are the most important causes of exacerbations, and that purulent sputum is the key sign which differentiates between the former and latter two aetiologies. Frequent exacerbations appear to be associated with worsening health outcomes, and efforts should focus on preventing these episodes or prompt effective treatment of each episode. However, treatment options are limited, and further research is needed to clarify the mechanisms that commence and sustain exacerbations to identify new therapeutic targets.

Authors' affiliations

E Sapey, R A Stockley, Lung Investigation Unit, Queen Elizabeth Hospital, Birmingham B15 2TH, UK

Funding: none.

Competing interests: none declared.

REFERENCES

- 1 Stockley RA. Neutrophils and the pathogenesis of COPD. *Chest* 2002;**121**:151–55.
- 2 Seemungal TA, Donaldson GC, Paul EA, *et al.* Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1998;**157**:1418–22.
- 3 Seemungal TA, Donaldson GC, Bhowmik A, *et al.* Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2000;**161**:1608–13.
- 4 Wedzicha JA. The heterogeneity of chronic obstructive pulmonary disease. *Thorax* 2000;**55**:631–2.
- 5 Pauwels RA, Buist AS, Calverley PM, *et al.* Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. *Am J Respir Crit Care Med* 2001;**163**:1256–76.
- 6 Anthonisen NR, Manfreda J, Warren CP, *et al.* Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. *Ann Intern Med* 1987;**106**:196–204.
- 7 Rodriguez-Roisin R. Towards a consensus definition for COPD exacerbations. *Chest* 2000;**117**:398–401s.
- 8 Finlay GA, Russell KJ, McMahon KJ, *et al.* Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. *Thorax* 1997;**52**:502–6.
- 9 Saetta MTG, Facchini FM, Corbino L, *et al.* Inflammatory cells in the bronchial glands of smokers with chronic bronchitis. *Am J Respir Crit Care Med* 1997;**156**:1633–9.
- 10 Rutgers SR, Timens W, Kaufmann HF, *et al.* Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. *Eur Respir J* 2000;**15**:109–15.
- 11 Stanescu D, Sanna A, Veriter C, *et al.* Airways obstruction, chronic expectoration and rapid decline in FEV₁ in smokers are associated with increased levels of sputum neutrophils. *Thorax* 1996;**51**:267–71.
- 12 Martin TR, Raghu G, Maunder RJ, *et al.* The effects of chronic bronchitis and chronic air flow obstruction on lung cell populations recovered by bronchoalveolar lavage. *Am Rev Respir Dis* 1985;**132**:260.
- 13 Traves SL, Culpitt SV, Russell RE, *et al.* Increased levels of the chemokine GRO α and MCP-1 in sputum samples from patients with COPD. *Thorax* 2002;**57**:590–5.
- 14 Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. *Am J Respir Crit Care Med* 1999;**160**:893–8.
- 15 Yamamoto C, Yoneda T, Yoshikawa M, *et al.* Airway inflammation in COPD assessed by sputum levels of interleukin-8. *Chest* 1997;**112**:505–10.
- 16 Balbi B, Bason C, Balleari E, *et al.* Increased bronchoalveolar granulocytes and granulocyte/macrophage colony stimulating factor during exacerbations of chronic bronchitis. *Eur Respir J* 1997;**10**:846–50.
- 17 Tsoumakidou M, Tzanakis N, Chrysosfakis G, *et al.* Changes in sputum T-lymphocyte subpopulations at the onset of severe exacerbations of chronic obstructive pulmonary disease. *Respir Med* 2005;**99**:572–9.
- 18 Selby C, Drost E, Lannan S, *et al.* Neutrophil retention in the lungs of patients with chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1991;**143**:1359–64.
- 19 Bhowmik A, Seemungal TAR, Sapsford RJ. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD. *Thorax* 2000;**55**:114–20.
- 20 Roland M, Bhowmik A, Sapsford RJ, *et al.* Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. *Thorax* 2001;**56**:30–5.
- 21 Hill AT, Bayley D, Campbell EJ, *et al.* Airways inflammation in chronic bronchitis; the effects of smoking and alpha1-antitrypsin deficiency. *Eur Respir J* 2000;**15**:886–90.

- 22 **Gerritsen WB**, Asin J, Zanen P, *et al*. Markers of inflammation and oxidative stress in exacerbated chronic obstructive pulmonary disease patients. *Respir Med* 2005;**99**:84–90.
- 23 **Malo O**, Sauleda J, Busquets X, *et al*. Systemic inflammation during exacerbations of chronic obstructive pulmonary disease. *Arch Bronconeumol* 2002;**38**:172–6.
- 24 **Stockley RA**, O'Brien C, Pye A, *et al*. Relationship to sputum colour to nature and out-patient management of acute exacerbations of COPD. *Chest* 2000;**117**:1638–45.
- 25 **Gompertz S**, O'Brien C, Bayley D, *et al*. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. *Eur Respir J* 2001;**17**:1112–9.
- 26 **Aaron SD**, Angel JB, Lunau M, *et al*. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2001;**163**:349–55.
- 27 **White AJ**, Gompertz S, Bayley DL, *et al*. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. *Thorax* 2003;**58**:680–5.
- 28 **Fujimoto K**, Yasuo M, Urushibaba K, *et al*. Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease. *Eur Respir J* 2005;**25**:640–6.
- 29 **Gerritsen WB**, Asin J, Zanen P, *et al*. Markers of inflammation and oxidative stress in exacerbated chronic obstructive pulmonary disease patients. *Respir Med* 2005;**99**:84–90.
- 30 **van Beurden WJ**, Smeenk FW, Harff GA, *et al*. Markers of inflammation and oxidative stress during lower respiratory tract infections in COPD patients. *Monaldi Arch Chest Dis* 2003;**59**:273–80.
- 31 **Zhu J**, Qiu YS, Majumdar S, *et al*. Exacerbations of bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. *Am J Respir Crit Care Med* 2001;**164**:3–4.
- 32 **Foxman EF**, Campbell JJ, Butcher EC. Multistep navigation and the combinatorial control of leukocyte chemotaxis. *J Cell Biol* 1997;**139**:1349–59.
- 33 **Liou TG**, Campbell EJ. Quantum proteolysis resulting from release of single granules by human neutrophils: a novel, nonoxidative mechanism of extracellular proteolytic activity. *J Immunol* 1996;**157**:2624–31.
- 34 **Hubbard RC**, Fells G, Gadek J, *et al*. Neutrophil accumulation in the lung in α_1 -antitrypsin deficiency: spontaneous release of leukotriene B₄ by alveolar macrophages. *J Clin Invest* 1991;**88**:891–7.
- 35 **Stockley RA**, Shaw J, Afford SC, *et al*. Effect of alpha one proteinase inhibitor on neutrophil chemotaxis. *Am J Respir Cell Mol Biol* 1990;**2**:163–70.
- 36 **Burnett D**. Neutrophils. In: Stockley RA, ed. *Pulmonary defenses*. Chichester: WileyEurope, 1997:113–26.
- 37 **Hill AT**, Campbell EJ, Hill SL, *et al*. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. *Am J Med* 2000;**109**:288–95.
- 38 **Stockley RA**, Bayley D, Hill SL, *et al*. Assessment of airway neutrophils by sputum colour: correlation with airways inflammation. *Thorax* 2001;**56**:366–72.
- 39 **Sethi S**, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000. A state of the art review. *Clin Microbiol Rev* 2001;**14**:336–63.
- 40 **Connors AF Jr**, Dawson NV, Tomas C, *et al*. Outcomes following acute exacerbations of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understanding Prognosis and Preferences for Outcomes and Risks of Treatment). *Am J Respir Crit Care Med* 1996;**154**:959–67.
- 41 **Groenewegen KH**, Schols AMWJ, Wouters EFM. Mortality and mortality-related factors after hospitalisation for acute exacerbation of COPD. *Chest* 2003;**124**:459–67.
- 42 **Hodgeve VA**, Kostianec SS, Torosian AA, *et al*. Long-term changes in dyspnea, lung function and exercise capacity in COPD patients. *Folia Med* 2004;**46**:12–7.
- 43 **Spencer S**, Calverley PMA, Burge S, Jones PW, ISOLDE Study Group. Health status deterioration in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2001;**163**:122–8.
- 44 **Donaldson GC**, Wilkinson TM, Hurst JR, *et al*. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2005;**171**:446–52.
- 45 **Viglio S**, Iadarola P, Lupi A, *et al*. MEKC of desmosine and isodesmosine in urine of chronic obstructive lung disease patients. *Eur Respir J* 2000;**15**:1039–45.
- 46 **Gottlieb DJ**, Stone PJ, Sparrow D, *et al*. Urinary desmosine excretion in smokers with and without rapid decline of lung function. The Normative Aging Study. *Am J Respir Crit Care Med* 1996;**154**:1290–5.
- 47 **Kosmas EN**, Zorpidou D, Vassilareas V, *et al*. Decreased CD4 complement component serum levels correlate with the degree of emphysema in patient with chronic bronchitis. *Chest* 1997;**112**:341–7.
- 48 **White AJ**, Gompertz S, Stockley RA. The aetiology of exacerbations of chronic obstructive pulmonary disease. *Thorax* 2003;**58**:73–80.
- 49 **Gompertz S**, Bayley DL, Hill SL, *et al*. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. *Thorax* 2001;**56**:36–41.
- 50 **Agerberth B**, Grunewald J, Castanos-velez E, *et al*. Antibacterial components in bronchoalveolar lavage fluid from healthy individuals and sarcoidosis patients. *Am J Respir Crit Care Med* 1999;**160**:283–90.
- 51 **Draper DL**, Landers DV, Krohn MA, *et al*. Levels of vaginal secretory leukocyte protease inhibitor are decreased in women with lower reproductive tract infections. *Am J Obstet Gynecol* 2000;**183**:1243–8.
- 52 **Wilkinson TM**, Patel IS, Wilks M, *et al*. Airway bacterial load and FEV₁ decline in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2003;**167**:1090–5.
- 53 **Ball P**. Epidemiology and treatment of chronic bronchitis and its exacerbations. *Chest* 1995;**108**:43–52S.
- 54 **Sunyer J**, Saez M, Murillo C, *et al*. Air pollution and emergency room admission for chronic obstructive pulmonary disease. *Am J Epidemiol* 1993;**137**:701–5.
- 55 **Monso E**, Ruiz J, Manterola J, *et al*. Bacterial infection in chronic obstructive pulmonary disease: a study of stable and exacerbated outpatients using the protected specimen brush. *Am J Respir Crit Care Med* 1995;**152**:1316–20.
- 56 **Fagon JY**, Chastre J, Trouillet JL, *et al*. Characterisation of distal bronchial microflora during acute exacerbation of chronic bronchitis. *Am Rev Respir Dis* 1990;**142**:1004–8.
- 57 **Pela R**, Marchesani FF, Agostinelli C, *et al*. Airways microbial flora in COPD patients in stable clinical conditions and during exacerbations, a bronchoscope investigation. *Monaldi Arch Chest Dis* 1998;**53**:262–7.
- 58 **Soler N**, Torres A, Ewig S, *et al*. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. *Am J Respir Crit Care Med* 1998;**157**:1498–505.
- 59 **Bogaert D**, van der Valk P, Ramdin R, *et al*. Host-pathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease. *Infect Immun* 2004;**72**:818–23.
- 60 **Sethi S**, Wrona C, Grant BJ, *et al*. Strain specific immune responses to Haemophilus influenzae in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2004;**169**:448–53.
- 61 **Murphy TF**, Brauer AL, Grant BJ, *et al*. Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. *Am J Respir Crit Care Med* 2005;**172**:195–9.
- 62 **Adler KB**, Hendly DD, Davis GS. Bacteria associated with obstructive pulmonary disease elaborate extracellular products that stimulate mucin secretion by explants of guinea pig airways. *Am J Pathol* 1986;**125**:501–14.
- 63 **Wilson R**, Roberts D, Cole P. Effects of bacterial products on human ciliary function in vitro. *Thorax* 1984;**40**:125–31.
- 64 **Read RC**, Wilson R, Rutman A, *et al*. Interaction of nontypable Haemophilus influenzae with human respiratory mucosa in vitro. *J Infect Dis* 1991;**163**:549–58.
- 65 **Solar N**, Ewig S, Torres A, *et al*. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. *Eur Respir J* 1999;**14**:1015–22.
- 66 **Khair OA**, Devalia JL, Abdelaziz MM, *et al*. Effect of Haemophilus influenzae endotoxin on the synthesis of IL-6, IL-8, TNF-alpha and expression of ICAM-1 in cultured human epithelial cells. *Eur Respir J* 1994;**7**:2109–16.
- 67 **Bresser P**, Out TA, van Alphen L, *et al*. Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic Haemophilus influenzae airway infection. Comparison with noninfected patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2000;**162**:947–52.
- 68 **Hirschmann JV**. Do bacteria cause exacerbations of COPD? *Chest* 2000;**118**:193–203.
- 69 **Stockley RA**. Chronic obstructive pulmonary disease, neutrophils and bacteria: from science to integrated care pathways. *Clin Med* 2004;**4**:567–72.
- 70 **Patel IS**, Seemungal TA, Wilks M, Lloyd-Owen SJ, *et al*. Relationship between bacterial colonisation and the frequency, character and severity of COPD exacerbations. *Thorax* 2002;**57**:759–64.
- 71 **Gump DW**, Phillips CA, Forsyth BR, *et al*. Role of infection in chronic bronchitis. *Am Rev Respir Dis* 1976;**113**:465–73.
- 72 **McHardy VU**, Inglis JM, Calder MA, *et al*. A study of infective and other factors in exacerbations of chronic bronchitis. *Chest* 1980;**74**:228–38.
- 73 **Bandi V**, Apicella MA, Mason E, *et al*. Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. *Am J Respir Crit Care Med* 2001;**164**:2114–9.
- 74 **Murphy TF**, Brauer AL, Schiffmacher AT, *et al*. Persistent colonisation by Haemophilus influenzae in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2004;**170**:266–72.
- 75 **Sethi S**. New developments in the pathogenesis of acute exacerbations of chronic obstructive pulmonary disease. *Curr Opin Infect Dis* 2004;**17**:113–9.
- 76 **Mobbs KJ**, van Saene HK, Sunderland D, *et al*. Oropharyngeal gram-negative bacillary carriage in chronic obstructive pulmonary disease. *Respir Med* 1999;**93**:540–5.
- 77 **Sethi S**. Infectious etiology of acute exacerbations of chronic bronchitis. *Chest* 2000;**117**:380–5S.
- 78 **Zalacain R**, Sobradillo V, Amilibia J, *et al*. Predisposing factors to bacterial colonisation in chronic obstructive pulmonary disease. *Eur Respir J* 1999;**13**:343–8.
- 79 **Packe GE**, Hodson ME. Changes in spirometry during consecutive admissions for infective pulmonary exacerbations in adolescent and adult cystic fibrosis. *Respir Med* 1992;**86**:45–8.
- 80 **Angrill J**, Agusti C, de Celis R, *et al*. Bacterial colonisation in patients with bronchiectasis: microbial pattern and risk factors. *Thorax* 2002;**57**:15–9.
- 81 **Chin CL**, Manzel LJ, Lehman EE, *et al*. Haemophilus influenzae from COPD patients with exacerbation induce more inflammation than colonizers. *Am J Respir Crit Care Med* 2005;**172**:85–91.
- 82 **Sethi S**, Wrona C, Grant BJ, *et al*. New strains of bacteria and exacerbations of chronic obstructive disease. *N Engl J Med* 2002;**347**:465–71.
- 83 **Carilli AD**, Gohd RS, Gordon W. A virological study of chronic bronchitis. *N Engl J Med* 1964;**270**:123.
- 84 **Monto AS**, Bryan ER. Susceptibility to rhinovirus infection in chronic bronchitis. *Am Rev Respir Dis* 1978;**118**:1101–3.

- 85 **Smith CB**, Golden C, Kanner RE, *et al.* Association of viral and mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary diseases. *Am Rev Respir Dis* 1980;**121**:225–32.
- 86 **Greenberg SB**, Allen M, Wilson J, *et al.* Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2000;**162**:167–73.
- 87 **Wedzicha JA**, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. *Respir Care* 2003;**48**:1204–15.
- 88 **Stenhouse AC**. Viral antibody levels and clinical status in acute exacerbations of chronic bronchitis: a controlled prospective study. *BMJ* 1968;**3**:287–90.
- 89 **Seemungal T**, Harper-Owen R, Bhowmik A, *et al.* Detection of rhinovirus in induced sputum at exacerbation of chronic bronchitis. *Eur Respir J* 2000;**16**:677–83.
- 90 **Seemungal TA**, Harper-Owen R, Bhowmik A, *et al.* Respiratory viruses, symptoms and inflammatory markers in acute exacerbations and stable chronic obstructive disease. *Am J Respir Crit Care Med* 2001;**164**:1618–23.
- 91 **Glezen WP**, Greenberg SB, Atmar RL, *et al.* Impact of respiratory virus infections on persons with chronic underlying conditions. *JAMA* 2000;**283**:499–505.
- 92 **Greenberg SB**, Allen M, Wilson J, *et al.* Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2000;**162**:167–73.
- 93 **Beckham JB**, Cadena A, Lin J, *et al.* Respiratory viral infections in patients with chronic obstructive pulmonary disease. *J Infect* 2005;**50**:322–30.
- 94 **Centres for Disease Control and Prevention**. *Influenza. A season summary, 2005*. Available at www.cdc.gov/flu/weekly/fluactivity/hm.
- 95 **Thompson WW**, Shay DK, Weintraub E, *et al.* Influenza-associated hospitalizations in the United States. *JAMA* 2004;**292**:1333–40.
- 96 **Thompson WW**, Shay DK, Weintraub E, *et al.* Mortality associated with influenza and respiratory syncytial virus in the United States. *JAMA* 2003;**289**:179–86.
- 97 **Falsey AR**, Hennessey PA, Formica MA, *et al.* Respiratory syncytial virus infection in elderly and high-risk adults. *N Engl J Med* 2005;**352**:1749–59.
- 98 **Borg I**, Rohde G, Loseke S, *et al.* Evaluation of a quantitative real-time PCR for the detection of respiratory syncytial virus in pulmonary diseases. *Eur Respir J* 2003;**21**:944–51.
- 99 **Van den Hoogen BG**, van Doornum GJ, Fockens JC, *et al.* Prevalence and clinical symptoms of human metapneumovirus infection in hospitalised patients. *J Infect Dis* 2003;**188**:1571–7.
- 100 **Hegele RG**, Hayashi S, Hogg JC, *et al.* Mechanisms of airway narrowing and hyperresponsiveness in viral respiratory tract infections. *Am J Respir Crit Care Med* 1995;**151**:1659–64.
- 101 **Papi A**, Johnston SL. Rhinovirus infection induces expression of its own receptor ICAM-1 via increased NF- κ B mediated transcription. *J Biol Chem* 1999;**274**:9707–20.
- 102 **Fiorini G**, Crespi S, Rinaldi M, *et al.* Serum ECP and MPO are increased during exacerbations of chronic bronchitis with airway obstruction. *Biomed Pharmacother* 2000;**54**:274–8.
- 103 **Saetta MP**, Di Stefano A, Maestrelli P, *et al.* Airway eosinophilia and expression of interleukin-5 protein in asthma and exacerbations of chronic bronchitis. *Clin Exp Allergy* 1995;**26**:766–74.
- 104 **Saetta MP**, Di Stefano A, Maestrelli P, *et al.* Airway eosinophilia in chronic bronchitis during exacerbations. *Am J Respir Crit Care Med* 1994;**150**:1646–52.
- 105 **Spurrell JC**, Wiehler S, Zaheer RS, *et al.* Human airway epithelial cells produce IP-10 (CXCL10) in vitro and in vivo upon rhinovirus infection. *Am J Physiol Lung Cell Mol Physiol* 2005;**289**:L85–95.
- 106 **Biagioli MC**, Kaul P, Singh I, *et al.* The role of oxidative stress in rhinovirus induced elaboration of IL-8 by respiratory epithelial cells. *Free Radic Biol Med* 1999;**26**:454–62.
- 107 **Mullol J**, Baraniuk JN, Logun C, *et al.* Endothelin-1 induces GM-CSF, IL-6, IL-8 but not G-CSF release from a human bronchial epithelial cell line (BEAS-2B). *Neuropeptides* 1996;**30**:551–6.
- 108 **Jacoby DB**. Interaction of viral infections with muscarinic receptors. *Clin Exp Immunol* 1999;**29**:59–64.
- 109 **Smith CB**, Golden C, Klauber MR, *et al.* Interactions between viruses and bacteria in patients with chronic bronchitis. *J Infect Dis* 1976;**134**:552–61.
- 110 **Lieberman D**, Lieberman D, Yaakov BM, *et al.* Infectious etiologies in acute exacerbations of COPD. *Diagn Microbiol Infect Dis* 2001;**40**:95–102.
- 111 **Chu HW**, Jeyaseelan S, Rino JG, *et al.* TLR2 signalling is critical for Mycoplasma pneumoniae induced airway mucin expression. *J Immunol* 2005;**174**:5713–9.
- 112 **Meloni F**, Paschetto E, Mangiarotti P, *et al.* Acute Chlamydia pneumoniae and Mycoplasma pneumoniae infections in community acquired pneumonia and exacerbations of COPD or asthma: therapeutic considerations. *J Chemother* 2004;**16**:70–6.
- 113 **Beatty CD**, Grayston JT, Wang SP. Chlamydia pneumoniae, strain TWAR, infections in patients with chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1991;**144**:1408–10.
- 114 **Rupp J**, Kothe H, Mueller A, *et al.* Imbalanced secretion of IL-1 β and IL-1RA in Chlamydia pneumoniae-infected mononuclear cells from COPD patients. *Eur Respir J* 2003;**22**:274–9.
- 115 **Ministry of Health**. *Mortality and morbidity during the London fog of December 1952*, Report No 95 on Public Health and Medical Subjects. London: Ministry of Health, 1954.
- 116 **World Health Organisation**. *Acute effects on health of smog episodes*. Copenhagen: World Health Organisation, 1992.
- 117 **Anderson HR**, Spix C, Medina S, *et al.* Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project. *Eur Respir J* 1997;**10**:1064–71.
- 118 **Cifuentes LA**, Vega J, Kopfer K, *et al.* Effect of the fine fraction of particulate matter versus the coarse mass and other pollutants on daily mortality in Santiago, Chile. *J Air Waste Manag Assoc* 2000;**50**:1287–98.
- 119 **Dockery DW**, Pope CAI, Xu X, *et al.* An association between air pollution and mortality in six US cities. *N Engl J Med* 1993;**329**:1753–9.
- 120 **MacNee W**, Donaldson K. Exacerbations of COPD. Environmental mechanisms. *Chest* 2000;**117**:390–7s.
- 121 **Pope CA**, Kanner RE. Acute effects of PM10 pollution on pulmonary function of smokers with mild to moderate chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1993;**147**:1336–40.
- 122 **Pope CAI**, Bates DV, Raizenne ME. Health effects of particulate air-pollution. *Environ Health Perspect* 1995;**103**:472–80.
- 123 **Jany B**, Gallup M, Tsuda T, *et al.* Mucin gene expression in rat airways following infection and irritation. *Biochem Biophys Res Commun* 1991;**181**:1–8.
- 124 **Li XY**, Gilmour PS, Donaldson K, *et al.* Free radical activity and pro-inflammatory effects of particulate air pollution (PM10) in vivo and in vitro. *Thorax* 1996;**51**:1216–22.
- 125 **Salvi SS**, Nordenhall C, Blomberg A, *et al.* Acute exposure to diesel exhaust increases IL-8 and GRO-alpha production in healthy human airways. *Am J Respir Crit Care Med* 2000;**161**:550–7.
- 126 **Pourazar J**, Mudway IS, Samet JM, *et al.* Diesel exhaust activates redox sensitive transcription factors and kinases in human airways. *Am J Physiol Lung Cell Mol Physiol* 2005;**289**:L724–30.
- 127 **Kopp MV**, Ulmer C, Ihost G, *et al.* Upper airway inflammation in children exposed to ambient ozone and potential signs of adaptation. *Eur Respir J* 1999;**14**:854–61.
- 128 **Devalia JL**, Rusnak C, Herdman MJ, *et al.* Effect of nitrogen dioxide and sulphur dioxide on airway response of mild asthmatic patients to allergen inhalation. *Lancet* 1994;**344**:1668–71.
- 129 **Donaldson GC**, Seemungal T, Jeffries DJ, *et al.* Effect of temperature on lung function and symptoms in chronic obstructive pulmonary disease. *Eur Respir J* 1999;**13**:844–9.
- 130 **Wongsurakiat P**, Maranetra KN, Gulprasutdilong P, *et al.* Adverse effects associated with influenza vaccination in patients with COPD: a randomized controlled study. *Respirology* 2004;**9**:550–6.
- 131 **Tata LJ**, West J, Harrison T, *et al.* Does influenza vaccination increase consultations, corticosteroid prescriptions, or exacerbations in subjects with asthma or chronic obstructive pulmonary disease? *Thorax* 2003;**58**:835–9.